METHODS AND RESULTS: As a prespecified secondary analysis of the CADILLAC trial, we compared early and late outcomes by
abciximab assignment among 2082 patients randomized in an open-label, 2x2 factorial-design trial of primary stenting versus angioplasty and
abciximab treatment (n=1052) versus no
abciximab treatment (n=1030). Baseline characteristics were balanced between groups.
Abciximab treatment was associated with a significant reduction in the composite end point of death, MI,
ischemia-driven target-vessel revascularization (TVR), or disabling
stroke at 30 days (4.6% versus 7.0%; relative risk, 0.65; 95% CI, 0.46 to 0.93; P=0.01). Subacute
thrombosis also was significantly reduced with
abciximab treatment. At 12 months, however, rates of the composite end point did not differ significantly (18.4% for controls versus 16.9% for
abciximab-treated patients; relative risk, 0.92; 95% CI, 0.76 to 1.10; P=0.29), reflecting a decrease in the relative difference in TVR rates (ie, no effect of
abciximab on reducing restenosis). In an angiographic substudy (n=656), myocardial salvage, restenosis, and
infarct-artery reocclusion at 7 months were unaffected by
abciximab treatment. There was no significant interaction between stenting and
abciximab treatment.
CONCLUSIONS: